Research
Baicalein
19 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
The effects of flavonoid baicalein on miRNA expressions in cancer: a systematic review.
Systematic review of baicalein's effects on miRNA expression in various cancers, including hepatocellular carcinoma, breast, cervical, ovarian, and gastric cancers. Baicalein influences key signaling pathways and processes like tumor growth, apoptosis, and metastasis, suggesting its potential as a multi-cancer therapeutic.
Research Progress on the Antidepressant Effects of Baicalin and Its Aglycone Baicalein: A Systematic Review of the Biological Mechanisms.
Systematic review of the antidepressant effects of baicalin and baicalein in experimental animal models. The review emphasizes molecular mechanisms such as regulation of the HPA axis, inhibition of inflammation and oxidative stress, reduction of neuronal apoptosis, promotion of neurogenesis, and amelioration of mitochondrial dysfunction.
Wogonin and its analogs for the prevention and treatment of cancer: A systematic review.
Systematic review evaluating the therapeutic potential and mechanisms of action of wogonin (WOG) against various cancers. Numerous in vitro and in vivo studies suggest WOG has therapeutic potential by regulating cell signaling pathways and improving the efficacy of chemotherapeutic drugs. Human trials are needed to validate these findings.
Modulation of diverse oncogenic signaling pathways by oroxylin A: An important strategy for both cancer prevention and treatment.
Systematic review of the anticancer effects of oroxylin A (OA), a flavonoid from various plants. The review evaluates OA's potential against multiple cancers and its chemosensitization and radiosensitization properties. Despite promising findings, the lack of pharmacokinetic studies and dose standardization limits its therapeutic optimization.
Preclinical Evidence and Possible Mechanisms of Baicalein for Rats and Mice With Parkinson's Disease: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of 20 studies assessing baicalein's neuroprotective effects in animal models of Parkinson's disease. Baicalein significantly improved neurobehavioral function and exerted effects through multiple mechanisms, including antioxidation and anti-inflammatory pathways.
The Biological Activities and Therapeutic Potentials of Baicalein Extracted from: A Systematic Review.
This systematic review presents in vivo and in vitro studies on the biological activities and therapeutic potential of baicalein, a bioactive constituent of a medicinal plant, for anti-cancer, antibacterial, anti-hyperglycemia, neurogenesis, cardioprotective, anti-adipogenesis, anti-inflammatory, and wound healing effects. The review highlights the scarcity of human clinical studies on baicalein.
Baicalin and its aglycone: a novel approach for treatment of metabolic disorders.
Systematic review of literature on baicalin and baicalein, major extracts from Scutellaria baicalensis, highlighting their hepatoprotective, anti-oxidative, anti-dyslipidemic, anti-lipogenic, anti-obese, anti-inflammatory, and anti-diabetic effects. The study focuses on their therapeutic applications against hyperglycemia, insulin resistance, type 2 diabetes, hyperlipidemia, obesity, and non-alcoholic fatty liver.
Investigation of baicalin, baicalein and low-dose sulfasalazine for orocecal transit time determination in saliva and plasma.
The study investigated the oral pharmacokinetics and conversion of baicalin and baicalein in conjunction with low-dose sulfasalazine for orocecal transit time determination. Baicalein showed an earlier plasma concentration onset compared to sulfapyridine, while baicalin's plasma appearance time was not significantly different. Baicalin was not secreted into saliva, and low-dose sulfasalazine was a reliable salivary marker for transit time determination.
Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled, single-dose phase I study.
This study evaluated the safety, tolerability, and pharmacokinetics of baicalein tablets in healthy Chinese subjects. A total of 80 subjects participated in a single-dose safety and pharmacokinetic study, with doses ranging from 100-800 mg. Baicalein was found to be safe and well-tolerated, with mild adverse events that resolved without intervention. Pharmacokinetic properties were assessed in both fasted and fed states.
Neuroprotective effects of baicalein in animal models of Parkinson's disease: A systematic review of experimental studies.
Systematic review of 16 studies assessing the neuroprotective effects of baicalein in animal models of Parkinson's disease. The review highlights baicalein's anti-oxidative, anti-apoptotic, and anti-inflammatory actions, as well as its effects on neurotransmitter balance and synuclein aggregation.
Safety and pharmacokinetics evaluation of oroxylin A in Chinese healthy volunteers: a phase I, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect study.
Phase I, double-blind, placebo-controlled study evaluating the safety and pharmacokinetics of oroxylin A in Chinese healthy volunteers. The study included single ascending dose, multiple dose, and food effect evaluations. No serious adverse events were reported, and the pharmacokinetic profile supports once-daily administration of oroxylin A, with recommendations to take it after meals.
Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study.
This study analyzed the safety and pharmacokinetic characteristics of baicalein tablets in 36 healthy Chinese subjects. Baicalein was generally safe and well-tolerated, with mild adverse events. It was rapidly absorbed with peak plasma levels reached within 2 hours after multiple administrations.
Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
Phase I randomized, double-blind, single-dose trial of baicalein (100-2800 mg) in 72 healthy adults to assess pharmacokinetics and safety. Baicalein was well tolerated with mild adverse events and no serious adverse events. Pharmacokinetic properties were characterized, and further clinical studies are warranted.
Systematic analysis of post-administrative saiboku-to urine by liquid chromatography to determine pharmacokinetics of traditional Chinese medicine.
Systematic analysis of post-administrative urine for Saiboku-To, an anti-asthmatic Chinese herbal remedy, using high-performance liquid chromatography (HPLC). The study identified eight components in the urine, including magnolol from Magnolia officinalis and other compounds from Glycyrrhiza glabra and Scutellaria baicalensis.
Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers.
This study investigated the pharmacokinetics, safety, and tolerability of baicalein in a multiple-ascending-dose protocol in healthy Chinese volunteers. Baicalein was administered in doses of 200, 400, and 800 mg, and pharmacokinetic parameters were assessed. The study found that baicalein was safe and well tolerated, with no serious accumulation observed.
Metabolites of baicalein in human urine.
The paper likely investigates the metabolites of baicalein in human urine, suggesting a focus on the pharmacokinetics or metabolism of baicalein.
Characteristics of delayed excretion of flavonoids in human urine after administration of Shosaiko-to, a herbal medicine.
Pharmacokinetic study of Shosaiko-to (TJ-9), a herbal medicine, in five healthy volunteers. HPLC analysis of urine revealed flavonoids such as liquiritigenin, baicalein, wogonin, and oroxylin A. The study identified different absorption and excretion profiles based on microflora activities, suggesting variations in metabolizer types among individuals.
A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein
The study applied a nano-cocrystal strategy to improve the dissolution rate and bioavailability of baicalein (BE). Baicalein-nicotinamide (BE-NCT) nano-cocrystals were prepared and evaluated both in vitro and in vivo, showing significant improvements in dissolution rate and bioavailability compared to BE coarse powder and other forms.
Lipoxygenase and cyclooxygenase inhibitors reveal a complementary role of arachidonic acid derivatives in pregnant human myometrium.
In vitro study on human myometrial strips from 24 pregnant women undergoing elective caesarean sections. The study assessed the effects of lipoxygenase inhibitors baicalein and AA861 on uterine contractility, showing tocolytic effects. Combined inhibition of COX and 12-LOX pathways resulted in additive tocolytic effects.